Skip to main content
Explore URMC
menu

Fatty Liver due to NASH and Obeticholic Acid (Trade name: Ocaliva)

Research Question:
Does the study medication Obeticholic Acid improve the overall survival and health of persons with nonalcoholic fatty liver disease, and resolve NASH?

Basic Study Information

Purpose:
Study participation is expected to last between 5-7 years. Participants will be randomized to take either 10mg, 25mg, or a placebo pill once daily of the study medication. A liver tissue biopsy is required up to 4 times over the course of the study, and 15 ultrasounds of your belly. Fasting blood work and vital signs will be taken at each clinic visit. Questionnaires and an EKG of your heart will be periodically done at clinic visits. All study medication and protocol required procedures are covered by the clinical trial sponsor.

Location: University of Rochester Medical Center
Study Reference #: 20151635

Lead Researcher (Principal Investigator)

Lead Researcher: Jonathan Huang

Study Contact Information

Study Coordinator: Chelsea DiBella, MPH
Phone: (585) 275-0803

Additional Study Details

Number of Visits:  More than 10
Parking:  Reimbursed
Transportation Coverage:  No
Reimbursement:  Yes

Want to participate in this study?

This field is required
This field is required
You must agree to be contacted to continue.


Return to Search